Skip to content
Screener

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Amgen logo
AmgenAMGN
2.8B0.0%
Biogen logo
BiogenBIIB
$100K0.0%
Gilead Sciences logo
Gilead SciencesGILD
5.6B0.0%
AbbVie logo
AbbVieABBV
$18M0.0%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemMarch 31, 2026(unaudited)December 31, 2025
Operating lease liability, net of current portion11,49312,032
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2928
Additional paid-in capital838,307809,765
Accumulated other comprehensive loss(146)(24)
Accumulated deficit(825,443)(772,559)
Total stockholders’ equity12,74737,210

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s common stock?
AnaptysBio, Inc. (ANAB) reported common stock of $29K in Q1 2026.
How has AnaptysBio, Inc.'s common stock changed year-over-year?
AnaptysBio, Inc.'s common stock decreased by 3.3% year-over-year, from $30K to $29K.
What is the long-term trend for AnaptysBio, Inc.'s common stock?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s common stock has grown at a 0.7% compound annual growth rate (CAGR), from $27K to $28K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about AnaptysBio, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude